Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Bik promotes proteasomal degradation to control low-grade inflammation
Yohannes A. Mebratu, … , Scott Randell, Yohannes Tesfaigzi
Yohannes A. Mebratu, … , Scott Randell, Yohannes Tesfaigzi
Published December 19, 2023
Citation Information: J Clin Invest. 2024;134(4):e170594. https://doi.org/10.1172/JCI170594.
View: Text | PDF
Research Article Inflammation

Bik promotes proteasomal degradation to control low-grade inflammation

  • Text
  • PDF
Abstract

Although chronic low-grade inflammation does not cause immediate clinical symptoms, over the longer term, it can enhance other insults or age-dependent damage to organ systems and thereby contribute to age-related disorders, such as respiratory disorders, heart disease, metabolic disorders, autoimmunity, and cancer. However, the molecular mechanisms governing low-level inflammation are largely unknown. We discovered that Bcl-2–interacting killer (Bik) deficiency causes low-level inflammation even at baseline and the development of spontaneous emphysema in female but not male mice. Similarly, a single nucleotide polymorphism that reduced Bik levels was associated with increased inflammation and enhanced decline in lung function in humans. Transgenic expression of Bik in the airways of Bik-deficient mice inhibited allergen- or LPS-induced lung inflammation and reversed emphysema in female mice. Bik deficiency increased nuclear but not cytosolic p65 levels because Bik, by modifying the BH4 domain of Bcl-2, interacted with regulatory particle non-ATPase 1 (RPN1) and RPN2 and enhanced proteasomal degradation of nuclear proteins. Bik deficiency increased inflammation primarily in females because Bcl-2 and Bik levels were reduced in lung tissues and airway cells of female compared with male mice. Therefore, controlling low-grade inflammation by modifying the unappreciated role of Bik and Bcl-2 in facilitating proteasomal degradation of nuclear proteins may be crucial in treating chronic age-related diseases.

Authors

Yohannes A. Mebratu, Jane T. Jones, Congjian Liu, Zerihun H. Negasi, Mizanur Rahman, Joselyn Rojas-Quintero, George T. O’Connor, Wei Gao, Josée Dupuis, Michael H. Cho, Augusto A. Litonjua, Scott Randell, Yohannes Tesfaigzi

×

Figure 2

A SNP affects BIK promoter activity and expression

Options: View larger image (or click on image) Download as PowerPoint
A SNP affects BIK promoter activity and expression
(A) AA of rs738276 de...
(A) AA of rs738276 demonstrates higher expression than GG (P = 2 × 10–11) in lymphoblastoid cells. (B) Bik mRNA in 40 HAECs from current or former smokers (11 AA, 20 AG, 9 GG). (C) HAECs (n = 23) differentiated and treated with 50 ng/ml IFN-γ. Bik was increased in Bik AA compared with Bik GG HAECs (P = 0.002). Western blot analysis of Bik protein in Bik AA and Bik GG HAECs. (D and E) p750A-SA or p750G-SA constructs were transfected into (D) HAECs and (E) H1299 cells, and BIK gene promoter activity of A normalized to G values. n = 3; N = 3. (F) IRF-1 has a higher affinity to p750G compared with p750A. Nuclear extracts from H1299 cells were subjected to EMSA using biotin-labeled p750A or p750G oligonucleotide probes of Bik and IRF-1 genes. (G) Primary HAECs with Bik AA and Bik GG genotypes were processed for ChIP assays by using anti–IRF-1 or control IgG (negative control). Precipitated DNA was subjected to PCR to amplify the Bik gene fragment. (H) Protein lysates from WT and IRF-CRISPR knockout HAECs subjected to Western blotting. (I) Cytosolic and nuclear fractions of BikAA and BikGG HAECs analyzed for expression of indicated proteins by Western blotting. (J) Plasma samples from individuals with Bik AA and Bik GG genotypes analyzed using Luminex. In each group, 40 samples were analyzed, and in many samples, these cytokines were not detected. (K) Metaanalysis of increased decline in lung function associated with G allele in study participants of more than 60 years of age in ECLIPSE, LSC, COPDGene, and FHS. Additive model compared GG, GA, and AA genotypes of BIK SNP rs738276 using GG as a reference group. Two-tailed Student’s t test compared between 2 groups, and grouped results were analyzed using 2-way ANOVA. Data are represented as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts